Literature DB >> 23520312

Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer.

Delphine Gourcerol1, Arnaud Scherpereel, Stephane Debeugny, Henri Porte, Alexis B Cortot, Jean-Jacques Lafitte.   

Abstract

There are no international guidelines for an appropriate and cost-effective follow-up for resected nonsmall cell lung cancer (NSCLC). We retrospectively reviewed the outcome of NSCLC patients after curative surgery. Follow-up included physical examination and chest radiography every 3 months, and chest computed tomography (CT) scan, bronchoscopy, abdominal ultrasound, brain CT scan and bone scan every 6 months for 3 years, then every year over the following 2 years. Prognostic factors and costs were analysed. Median overall survival following surgery for NSCLC in 162 patients was 38.5 months. Recurrence occurred in 85 (52.5%) patients including 41 (48%) symptomatic subjects. Disease-free survival was similar between patients with asymptomatic recurrence versus symptomatic patients (11.4 versus 12 months; p=0.41). Recurrence was detected by physical examination or chest radiography in 47 (55.3%) patients. Curative-intent therapy was provided in 18 (41%) out of 44 patients with asymptomatic recurrence and in four (10%) out of 41 symptomatic cases (p=0.001). Median overall survival from time of recurrence was higher in asymptomatic patients than in symptomatic patients (15.5 versus 7.2 months; p=0.001). The cost per year of life gained was USD32 700 (€22 397). An extensive follow-up, with acceptable cost, may improve the outcome of patients with resected NSCLC through detection of asymptomatic recurrences; however, validation by prospective studies is required.

Entities:  

Mesh:

Year:  2013        PMID: 23520312     DOI: 10.1183/09031936.00086712

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non-small-cell Lung Cancer.

Authors:  Quoc-Anh Ho; Nima K Harandi; Megan E Daly
Journal:  Clin Lung Cancer       Date:  2016-11-21       Impact factor: 4.785

2.  Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more.

Authors:  Angel Moran; Megan E Daly
Journal:  Transl Lung Cancer Res       Date:  2019-12

3.  Imaging surveillance and survival for surgically resected non-small-cell lung cancer.

Authors:  Leah M Backhus; Farhood Farjah; Chao-Kang Jason Liang; Hao He; Thomas K Varghese; David H Au; David R Flum; Steven B Zeliadt
Journal:  J Surg Res       Date:  2015-06-25       Impact factor: 2.192

Review 4.  Surveillance imaging following definitive radiotherapy for non-small cell lung cancer: What is the clinical impact?

Authors:  Brandon A Dyer; Megan E Daly
Journal:  Semin Oncol       Date:  2018-02-09       Impact factor: 4.929

Review 5.  Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms.

Authors:  Frank Griesinger; Julia Roeper; Christoph Pöttgen; Kay C Willborn; Wilfried E E Eberhardt
Journal:  Oncotarget       Date:  2018-10-12

6.  Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure.

Authors:  Dai Sonoda; Yosuke Matsuura; Yasuto Kondo; Junji Ichinose; Masayuki Nakao; Hironori Ninomiya; Yuichi Ishikawa; Makoto Nishio; Sakae Okumura; Yukitoshi Satoh; Mingyon Mun
Journal:  Thorac Cancer       Date:  2020-09-22       Impact factor: 3.500

7.  Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection.

Authors:  Ching-Yang Wu; Jui-Ying Fu; Ching-Feng Wu; Ming-Ju Hsieh; Yun-Hen Liu; Yi-Cheng Wu; Cheng-Ta Yang; Ying-Huang Tsai
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.